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The nucleoside analog 2’,3’-dideoxycytidine  (ddcyd) 
has been shown to inhibit the infectivity and cytopathic 
effect of human immunodeficiency virus on human 
OKT4+ lymphocytes in vitro (1). Metabolism of ddCyd 
by  human T-lymphoblastic cells (Molt 4) negative for 
human immunodeficiency virus and OKT4 was exam- 
ined. Molt 4 cells accumulated ddCyd and its phospho- 
rylated derivatives into acid-soluble and acid-insoluble 
material in a dose-dependent manner. For each concen- 
tration tested, 2‘,3’-dideoxycytidine triphosphate rep- 
resented 40% of the total acid-soluble pool  of  ddCyd 
metabolites. Uptake of 5 PM ddCyd was linear for 4 h 
after addition of drug. Efflux of ddCyd metabolites 
from cells followed a biphasic course with an initial 
retention half-life of 2.6 h for 2’,3‘-dideoxycytidine 
triphosphate. DNA, but not RNA, of cells incubated 
with [‘HIddCyd became radiolabeled. Nuclease and 
phosphatase treatment of DNA followed by reverse- 
phase high pressure liquid chromatography showed 
that the nucleoside was incorporated into DNA in  its 
original form. ddCyd was not susceptible to deamina- 
tion by human Cyd-dCyd deaminase. It was a poor 
substrate for human cytoplasmic and mitochondrial 
dCyd kinases,  with K,,, values of 180 f 30 and 120 2 
20 PM, respectively. DNA polymerases a, 8, and y var- 
ied in their sensitivity to inhibition by  ddCTP with Ki 
values of 110 f 40, 2.6 f 0.3, and 0.016 f 0.008 PM, 
respectively;  however, inhibition was competitive with 
dCTP in each case. 
Acquired immunodeficiency syndrome (AIDS)’ has 
emerged as  a major health threat in the last several years. 
Human immunodeficiency virus (HIV) is now recognized as 
the etiological agent of this disease (2-8). This virus prefer- 
entially infects and destroys OKT4’ (helper inducer) T-lym- 
phocytes (6). In AIDS and its preceding lymphadenopathy 
syndrome, there is detectable virus replication as determined 
by the presence of particulate reverse transcriptase activity 
(2) .  This raises the possibility of preventing or slowing the 
progress of the disease by early detection and blocking viral 
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replication with specific inhibitors of HIV  reverse transcrip- 
tase. 
It was recently reported that 2‘,3‘-dideoxypurine and 
-pyrimidine nucleosides inhibited the infectivity and cyto- 
pathic effect of HIV toward OKT4’ cells in vitro at concen- 
trations  that did not  inhibit proliferation in response to T 
cell mitogens (1). ddCyd was the most potent of the com- 
pounds tested and completely blocked the viral cytopathic 
effect at concentrations greater than 0.5 PM, a dosage at least 
10-fold less than that which inhibited cell growth in the 
absence of virus. 
The activity of ddCyd against HIV and  its low cytotoxicity 
make it  an attractive candidate for clinical trial; therefore, it 
is important to study  its metabolism in human cells.  We have 
chosen a T-lymphoblastic cell line (Molt 4) for these studies 
and report here on the uptake, efflux, phosphorylation, deam- 
ination,  and incorporation into DNA of ddCyd. 
MATERIALS AND METHODS~ 
RESULTS 
Uptake of ddCyd-Molt 4 cells were incubated with 2,5, or 
10 PM [3H]ddCyd for 6 h, and  the uptake into acid-soluble 
and acid-insoluble fractions was analyzed. As seen in Table 
1, there was a concentration-dependent uptake into both 
fractions, although incorporation of [3H]ddCyd into the acid- 
insoluble pool  was only a small percentage of the total. When 
the acid-soluble fractions were analyzed by anion exchange 
HPLC (Fig. l ) ,  there were three major metabolites in addition 
to a peak which coeluted with a ddCyd marker and  an uni- 
dentified “solvent breakthrough” peak. The metabolite which 
eluted in fraction 37  was in a position identical to authentic 
ddCTP. Metabolites of ddCyd which eluted in fractions 11 
and 23 were identified as  ddCMP  and ddCDP, respectively, 
on the basis of their elution positions with respect to dCMP 
and dCDP and by identification of the original nucleoside 
(ddCyd) after  phosphatase  treatment (see below). The amount 
of each metabolite found in cells was dependent on the extra- 
cellular concentration of ddCyd, and  the proportion of the 
total acid-soluble radioactivity represented by each metabolite 
remained the same. In each case, ddCMP, ddCDP, and  ddCTP 
represented approximately 30, 10, and 40%, respectively, of 
the  total acid-soluble radioactive pool. 
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When the acid-soluble fraction from cells treated with 10 
PM ddCyd was treated  with  alkaline  phosphatase  and venom 
phosphodiesterase, the radioactivity associated with each me- 
tabolite decreased, and  there was a corresponding increase in 
radioactivity associated with [3H]ddCyd. A portion of this 
phosphatase-treated  extract was analyzed on a reverse-phase 
CIS column, and more than 90% of the radioactivity coeluted 
with authentic ddCyd (data  not shown). This system com- 
pletely separates ddCyd, which elutes at 10.4 min from  Cyd 
and dCyd,  which elute at 4.5 and 5.3 min, respectively. 
Uptake and Efflux of ddCyd with Time-Cells  were incu- 
bated for 2, 4, or 6 h with 5 p~ ddCyd, a concentration 
approximately equal to  the ID50 in this cell line (data not 
shown). The  uptake of ddCyd and formation of its phospho- 
rylated metabolites were linear with time for 4 h after  addition 
of drug (Fig. 2A). Efflux of ddCyd and  its metabolites after 
resuspension of cells in drug-free medium followed a biphasic 
course, with an initial  retention half-life for the triphosphate 
of 2.6 h (Fig. 2 B ) .  When all phosphory~ated metabolites of 
ddCyd  were included in  this calculation, the initial  retention 
half-life was 5.7 h. 
I ~ o r ~ r a t i o n  f ddCyd into Nucleic Acidt+"urified nucleic 
acids from Molt 4 cells treated for 12 h with 5 p~ 13H]ddCyd 
were subjected to ultracentrifugation in a Cs2S04 gradient. 
There was one major peak of radioactivity which corresponded 
to  the position of DNA in the gradient (Fig. 3). It is uncertain 
at  this time  whether or not the small amounts of radioactivity 
associated with RNA represent  true incorporation, and more 
sensitive techniques must be  employed to address this ques- 
tion. Nucleic acids digested with micrococcal nuclease, venom 
phosphodiesterase, and alkaline  phosphatase were analyzed 
on a reverse-phase CIS  HPLC column. The majority of the 
radioactivity eluted in a position identical to  that of authentic 
ddCyd (Fig. 4). The amount and position of radioactive ma- 
terial which eluted before ddCyd varied in different experi- 
ments  and were most likely due to incomplete digestion of 
nucleic acids. 
Susceptibility of ddCyd  to Deamination-Since only three 
major phosphorylated metabolites of ddCyd  were seen on the 
anion exchange HPLC profiles after incubation of cells with 
ddCyd, it was expected that ddCyd  would not be significantly 
susceptible to deamination. That  this was indeed the case is 
shown in Fig. 5A. When 0.4 mM ddCyd  was incubated with 
10  units/ml  human Cyd-dCyd deaminase for periods up  to 90 
min, there was no significant catabolism of this compound. 
In addition, as seen in Fig. 5B, ddCyd interfered only slightly 
with deamination of dCyd. Deamination of 100 p~ dCyd  was 
90% of control  in the presence of 1 mM ddCyd after 30 min. 
Phosphorylation of ddCyd-As shown in Table 2, ddCyd 
was a poor substrate for both cytoplasmic and mitochondrial 
dCyd kinase activities, with K, values of 180 2 30 and 120 2 
20 pM, respectively. In addition to a high K,,, value, the 
maximum rate of ddCyd phospho~lation was significantly 
less than  that for dCyd with both enzymes. 
Inhibition of Human DNA Polymerases-The three major 
human DNA polymerases varied widely in  their susceptibility 
to inhibition by ddCTP; however, inhibition was competitive 
with dCTP for each enzyme. Polymerase y was by far  the 
most sensitive, with a h: value 19-fold less than  the Km value 
for dCTP. Polymerase CY was quite resistant to inhibition, 
with a Ki value for ddCTP greater than 100 times its K, for 
dCTP. Polymerase @ was intermediate in sensitivity with a 
KJKi  ratio of 1:l.i'. K; values for ddCTP against DNA 
polymerases CY, 6, and y were 110 A 40,  2.6 & 0.3, and 0.016 A 
0.008 p ~ ,  respectively. 
DISCUSSION 
The data presented show that significant amounts of 
ddCTP are formed in Molt 4 cells, with the uptake and 
phosphorylation of ddCyd dependent on its extracellular con- 
centration. ddCTP is a substrate for at least one of the 
mammalian DNA polymerases since it is incorporated into 
DNA. Whether or not the small amounts of incorporation 
can account for the cytotoxicity of ddCyd is  under investiga- 
tion. The relative sensitivities of DNA polymerases a, @, and 
y to inhibition by ddCTP  are similar to those noted by other 
investigators with ddTTP (14-16) and indicate that polym- 
erases @ and/or y are the most likely targets for inhibition. 
The observation that polymerase CY, the major enzyme in- 
volved in cellular DNA replication (15), is quite  resistant to 
inhibition by ddCTP may explain the relatively low cytotox- 
icity of ddCyd. 
Disappearance of ddCyd metabolites from cells followed a 
biphasic course, with an initial retention half-life for the 
triphosphate of 2.6 h. This value is less than  the 4-h half-life 
reported previously for 1-P-D-arabinofuranosylcytosine tri- 
phosphate  and approximately equal to  the half-life of ~ - P - D -  
arabinofuranosyi-5-azacytosine triphosphate in Molt 4 cells 
(10). The biphasic efflux phenomenon may be related to  the 
concentration dependence of enzymatic dephosphorylation of 
ddCTP, such that when the  ddCTP concentration  nears the 
K,,, value for this process, a slower rate of degradation occurs. 
It should be noted that ddCTP  accumuiat~on will be deter- 
mined not only by the rate of dephosphorylation, but also by 
the rates of phosphorylation and incorporation into nucleic 
acids; therefore, it is conceivable that different cell types may 
vary greatly in their ability to accumulate ddCTP  and  thus  in 
their susceptibility to ddCyd cytotoxicity. 
The studies with human Cyd-dCyd deaminase show that 
ddCyd is not significantly susceptible to deamination, a major 
pathway for inactivation of 1-P-D-arabino~ranosylcytosine 
in  humans (17). 
The greater potency of ddCyd compared to other dideox- 
ynucleosides to protect  against the cytopathic effect of HIV 
(1) could be due to differences in phosphorylation of these 
compounds if inhibition of reverse transcriptase by the  tri- 
phosphate  is  their mechanism of action as postulated. How- 
ever, the amounts of phosphorylated ddCyd derivatives 
formed in cells is small compared to formation of phospho- 
rylated metabolites of other dCyd analogs (10). Indeed, as 
shown here, ddCyd is a very  poor substrate for both kinases 
responsible for monophosphorylation of dCyd. It is not  certain 
at this time which  dCyd kinase, cytoplasmic or mitochondrial, 
is responsible for the majority of ddCyd monophosphorylation 
in Molt 4 cells. There  is no evidence at this time that HIV 
induces any unique nucleoside-metabolizing enzymes; there- 
fore, it is likely that one of these kinases is responsible for 
phosphorylation of ddCyd in HIV-infected cells. 
Unpublished results3 from this laboratory using homopol- 
ymer primer/template combinations and purified HIV reverse 
transcriptase indicate that ddTTP and ddGTP are potent 
inhibitors of this enzyme with Ki values in the nanomolar 
range. It is unfortunate that inhibition by ddCTP  cannot be 
examined using this system since HIV reverse transcriptase 
will not use a poly(dG)-oligo(dC) template; however, it is 
likely that  the enzyme has a low Ki value for ddCTP  as well. 
The small amounts of ddCTP formed in cells may be sufficient 
to inhibit the viral reverse transcriptase without much effect 
on cellular DNA polymerases, thus explaining the selective 
antiviral effect. 
3Cheng, Y.-C., Dutschman, G. E., Bastow, K. F., Sarngadharan, 
M. G., and Ting, R. Y. C. (1987) J. B i d  Chen., in press. 
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Several compounds in addition to ddCyd  have  been  shown 
to be active against HIV in vitro (18-22). The clinical expe- 
rience with these compounds is too limited to allow conclu- 
sions concerning their potential usefulness in slowing the 
progression of AIDS; however, there  has been  some cause to 
be optimistic (23, 24), especially when treatment  is  instituted 
early in the course of this disease. This study on the metab- 
olism of ddCyd represents a contribution to the body  of 
knowledge  needed about  any compound with potential use- 
fulness in the clinic. A detailed study of the mechanism of 
ddCyd cytotoxicity is now in progress. 
Note Added in Proof-During preparation of this manuscript, a 
paper which described phosphorylation of ddCyd by various cell types 
appeared in Bwchem. Phurmacol. (Cooney, D. A., Dalal, M., Mitsuya, 
H., McMahon, M. B., Nadkarni, M., Balzarini, J., Broder, S., and 
Johns, D.  G. (1986) Biochem. Phrmacol. 35,2065-2068). 
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